PharmaPack kits will initially be available in California, Mississippi, Arkansas, Connecticut, and Alabama, with plans to expand nationwide in the coming weeks. Prescribers can access PharmaPack ...
Harrow, Inc.'s stock price has fallen due to disappointing earnings releases in Q1, Q2, and Q3 of 2023. The company's various revenue buckets have not performed as well as expected, leading to a ...
Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% ...
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the execution of a five-year strategic supply and development (“SSD”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results